GlassScriptPhysician profile
Martin J Marak
NPI 1760923064
$3,028.62
in general payments reported to CMS, 2019-2025
20 companies · $788 in 2025
The $788 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $160 · 2021: $215 · 2023: $16.12 · 2024: $1,850 · 2025: $788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Travel and Lodging: $1,228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.32 |
| Travel and Lodging | $1,227.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,677.05 | 2024 | Evoque |
| Abbott Laboratories | $214.61 | 2021 | |
| Cleerly, INC. | $201.46 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| E.R. Squibb & Sons, L.L.C. | $175.71 | 2024-2025 | Camzyos |
| Ancora Heart, INC. | $155.04 | 2025 | Accucinch |
| Merck Sharp & Dohme LLC | $124.95 | 2019 | |
| Abiomed | $86.93 | 2024-2025 | Impella |
| Medtronic, INC. | $74.86 | 2025 | Linq II, Aurora Ev-Icd Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $45.20 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $44.53 | 2025 | |
| Heartflow, INC. | $37.97 | 2024-2025 | |
| Novo Nordisk INC | $34.31 | 2025 | Wegovy |
| Amgen INC. | $30.47 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $21.07 | 2024 | Watchman Flx |
| Cordis US Corp. | $20.33 | 2024 | Mynx Venous Vcd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.21 | 2019 | |
| Pfizer INC. | $16.41 | 2025 | |
| Kestra Medical Technology Services, INC. | $16.38 | 2025 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $16.12 | 2023 | Xarelto |
| Kiniksa Pharmaceuticals International, Plc | $16.01 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Marak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.